Tenderwize
Retour à la recherche

Open House Drug Discount Agreement Vilanterol/Umeclidiniumbromide

AOK Bayern - Die Gesundheitskasse·München, Germany·Deadline Apr 03, 2028 · 583 days left·Open·Supplies·Framework
Inscrivez-vous pour sauvegarderOpen documents
Structured notice only
Titre original de l'avis

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Vilanterol und Umeclidiniumbromid, ATC R03AL03

40/100

Score d'opportunité

Needs reviewLow complexity
SuppliesFrameworkOpen
Pourquoi ce score ?

Opportunité

40 / 100

Complexité

20 / 100

Facteurs de risque

No estimated value or volume provided. The open-house model offers no commitment to purchase, so revenue is unpredictab...

The agreement automatically lapses if a standard discount contract (via formal procurement) is concluded for the same a...

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until May 2028
  • Pharmaceutical products: Vilanterol and Umeclidiniumbromid (ATC R03AL03)
  • Non-exclusive discount agreements under §130c SGB V
Afficher le résumé complet

Open-house model for non-exclusive drug discount agreements for Vilanterol/Umeclidiniumbromid (ATC R03AL03) by AOK Bayern. Any eligible pharmaceutical company can join; no competition, but no guaranteed volume or value. Contracts run from earliest 01.06.2026 to 31.05.2028. Deadline for applications is 03.04.2028, but contracts can be concluded monthly if applications are complete by the 3rd of each month.

Risques

No estimated value or volume provided. The open-house model offers no commitment to purchase, so revenue is unpredictab...

The agreement automatically lapses if a standard discount contract (via formal procurement) is concluded for the same a...

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Must be a pharmaceutical company (pharmazeutischer Unternehmer)

Administrative

  • Submit signed contract, annex 'Festlegung der vertragsgegenständlichen Arzneimittel', and self-declaration of reliability
  • Documents may be submitted in paper form (signed by hand, 2 copies) or electronically with qualified electronic signature via dtvp.de

Les exigences peuvent être incomplètes.

Acheteur

Localisation

München, DEU

Site web

www.aok.de

Profil acheteur

Ouvrir le profil

Identifiant

DE811695320

Activité

Health

Lots (1)

LOT-0001

Open House Drug Discount Agreement Vilanterol/Umeclidiniumbromide

Non-exclusive discount agreement for pharmaceutical products with active substances Vilanterol and Umeclidiniumbromid (ATC R03AL03). All interested pharmaceutical companies meeting eligibility can join. No selection; all accepted. Contract duration 24 months, with possible early termination if other agreements supersede.

SuppliesFrameworkEU fundedElectronic submission

Localisation

DE212, Germany

Durée

May 2026 - May 2028

Catégorie

Pharmaceutical products

Date limite

Deadline Apr 03, 2028

Détails de la procédure

Date de publication
14 Apr 2026
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
254799-2026

Documents (2)

Document de consultation 1Portail de soumission 1

Appels d'offres similaires

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30